Chronic activation of ERK and neurodegenerative diseases

BioEssays

Volumn 25, Issue 11, 2003, Pages 1085-1095

  Colucci D'Amato, Luca ^a   Perrone Capano, Carla ^b   Di Porzio, Umberto ^c  

^a CNR   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1;

CELL COMPARTMENTALIZATION; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; DEGENERATIVE DISEASE; ENZYME ACTIVATION; ENZYME KINETICS; ENZYME LOCALIZATION; ENZYME SPECIFICITY; NERVE CELL PLASTICITY; NERVE DEGENERATION; PROTEIN FAMILY; REVIEW;

ANIMALS; CELL DIVISION; CELL SURVIVAL; ENZYME ACTIVATION; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NEURODEGENERATIVE DISEASES; NEURONS; SIGNAL TRANSDUCTION;

EID: 0242551370     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.10355     Document Type: Review

References (89)

1. Shoulson I. Experimental therapeutics of neurodegenerative disorders: unmet needs. Science 1998;282:1072-1074.
2. Bonifati V, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299:256-259.
3. Zuccato C, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001;293:493-498.
4. Sweatt DJ. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 2001;76:1-10.
5. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999;19:2435-2444.
6. Muda M, Boschert U, Dickinson R, Martinou JC, Martinou I, Camps M, Schlegel W, Arkinstall S. MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. J Biol Chem 1996;271:4319-4326.
7. Brondello JM, Pouysségur J, McKenzie FR. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 1999:286:2514-2517.
8. Camps M, Nichols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J 2000;14:6-16.
9. Zhou B, Wang ZX, Zhao Y, Brautigan DL, Zhang ZY. The specificity of extracellular signal-regulated kinase 2 dephosphorylation by protein phosphatases. J Biol Chem 2002;277:31818-31825.
10. Keyse SM. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr Opin Cell Biol 2000;12:186-192.
11. Vossler MR, Yao H, York RD, Pan MG, Rim CS, Stork PJ. cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 1997;89:73-82.
12. Impey S, Obrietan K, Storm D. Making new connections: role of ERK/MAP kinase signaling in neuronal plasticity. Neuron 1999;23:11-14.
13. Bading H, Greenberg ME. Stimulation of protein tyrosine phosphorylation by NMDA receptor activation. Science 1991;253:912-914.
14. Yuan XB, Jin M, Xu X, Song YQ, Wu CP, Poo MM, Duan S. Signalling and crosstalk of Rho GTPases in mediating axon guidance. Nat Cell Biol 2003;5:38-45.
15. Park S-H, Zarrinpar A, Lim WA. Rewiring MAP Kinase Pathways Using Alternative Scaffold Assembly Mechanisms. Science 2003;299:1061-1064.
16. Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL, Davis RJ. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 1997;277:693-696.
17. Xia XG, Harding T, Weller M, Bieneman A, Uney JB, Schulz B. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98:10433-10438.
18. Segal RA, Greenberg ME. Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci 1996;19:463-489.
19. Grewal SS, York RD, Stork P JS. Extracellular-signal-regulated kinase signalling in neurons. Curr Opin Neurobiol 1999;9:544-555.
20. Howe AK, Aplin AE, Juliano RL. Anchorage-dependent ERK signaling-mechanisms and consequences. Curr Opin Genet Dev 2002;12:30-35.
21. Fitzpatrick JL, Mize AL, Wade CB, Harris JA, Shapiro RA, Dorsa DM. Estrogen-mediated neuroprotection against beta-amyloid toxicity requires expression of estrogen receptor alpha or beta and activation of the MAPK pathway. J Neurochem 2002;82:674-682.
22. Sawada H, Ibi M, Kihara T, Honda K, Nakamizo T, Kanki R, Nakanishi M, Sakka N, Akaike A, Shimohama S. Estradiol protects dopaminergic neurons in a MPP+ Parkinson's disease model. Neuropharmacology 2002;42:1056-1064.
23. Martin JC, Michael D, Rose JC, Barad M, Casadlo A, Zhu H, Kandel ER. MAP kinase translocates into the nucleus of the presynaptic cell and is required for long-term facilitation in Aplysia. Neuron 1997;18:899-912.
24. Atkins CM, Selcher JC, Petraitis JJ, Trzaskos JM, Sweatt JD. The MAPK cascade is required for mammalian associative learning. Nature Neurosci 1998;1:602-609.
25. Adams JP, Sweatt JD. Molecular psychology: roles for the ERK MAP kinase cascade in memory. Annu Rev Pharmacol Toxicol 2002;42:135-163.
26. Di Cristo G, Berardi N, Cancedda L, Pizzorusso T, Putignano E, Ratto GM, Maffei L. Requirement of ERK activation for visual cortical plasticity. Science 2001;14:265-275.
27. Volmat V, Camps M, Arkinstall S, Pouysségur J, Lenormand P. The nucleus, a site for signal termination by sequestration and inactivation of p42/p44 MAP kinases. J Cell Science 2001;114:3433-3443.
28. Horgan AM, Stork PJ. Examining the mechanism of Erk nuclear translocation using green fluorescent protein. Exp Cell Res 2003;285:208-220.
29. Whitehurst AW, Wilsbacher JL, You Y, Luby-Phelps K, Moore MS, Cobb MH. ERK2 enters the nucleus by a carrier-independent mechanism. Proc Natl Acad Sci USA 2002;99:7496-7501.
30. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouysségur J. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J 1999;18:664-674.
31. Colucci-D'Amato GL, D'Alessio A, Califano D, Cali G, Rizzo C, Nitsch L, Santelli G, de Franciscis V. Abrogation of nerve growth factor-induced terminal differentiation by ret oncogene involves pertubation of nuclear translocation of ERK. J Biol Chem 2000;275:19306-19314.
32. Le Douarin N, Kalcheim C. The Neural Crest Second Edition, Cambridge University Press. 1999.
33. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 1976;73:2424-2428.
34. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994;77:841-852.
35. York RD, Yao H, Dillon T, Ellig CL, Eckert SP, McCleskey EW, Stork PJ. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature 1998;392:622-626.
36. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-185.
37. Tombes RM, Auer KL, Mikkelsen R, Valerie K, Wymann MP, Marshall CJ, McMahon M, Dent P. The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic. Biochem J 1998;330:1451-1460.
38. van Pujenbroek AA, van Weering DH, van den Brink CE, Bos JL, van der Saag PT, de Laat SW, den Hertog J. Cell scattering of SK-N-MC neuroepithelioma cells in response to Ret and FGF receptor tyrosine kinase activation is correlated with sustained ERK2 activation. Oncogene 1997;14:1147-1157.
39. Lenormand P, Sardet C, Pages G, L'Allemain G, Brunet A, Pouysségur J. Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts. J Cell Biol 1993;122:1079-1088.
40. Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 2002;4:556-564.
41. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994;265:966-970.
42. Hoshino R, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813-822.
43. Sebolt-Leopold JS, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5:810-816.
44. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997;272:2927-2935.
45. Colucci-D'Amato GL, D'Alessio A, Filliatreau G, Florio T, Di Giamberardino L, Chiappetta G, Vecchio G, Fusco A, Santoro M, de Franciscis V. Presence of physiologically stimulated RET in adult rat brain: induction of RET expression during nerve regeneration. Cell Growth Differ 1996;7:1081-1086.
46. Trupp M, Belluardo N, Funakoshi H, Ibanez CF. Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS. J Neurosci 1997 May 15;17:3554-3567.
47. Airaksinen MS, Titievsky A, Saarma M. GDNF family neurotrophic factor signaling: four masters, one servant? Mol Cell Neurosci 1999;13:313-325.
48. Ponder BA, Smith D. The MEN II syndromes and the role of the ret protooncogene. Adv Cancer Res 1996;70:179-222.
49. Rizzo C, et al. Ligand stimulation of a Ret chimeric receptor carrying the activating mutation responsible for the multiple endocrine neoplasia type 2B. J Biol Chem 1996;271:29497-29501.
50. Califano D, D'Alessio A, Colucci-D'Amato GL, De Vita G, Monaco C, Santelli G, Di Fiore PP, Vecchio G, de Franciscis V. A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells. Proc Natl Acad Sci USA 1996;93:7933-7937.
51. Califano D, Rizzo C, D'Alessio A, Colucci-D'Amato GL, Call G, Cannada Bartoli P, Santelli G, Vecchio G, de Franciscis V. Signaling through Ras is essential for ret oncogene-induced cell differentiation in PC12 cells. J Biol Chem 2000;275:19297-19305.
52. Robinson MJ, Stippec SA, Goldsmith E, White MA, Cobb MH. A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr Biol 1998;8:1141-1150.
53. Hempstead BL, Rabin SJ, Kaplan L, Reid S, Parada LF, Kaplan DR. Overexpression of the trk tyrosine kinase rapidly accelerates nerve growth factor-induced differentiation. Neuron 1992;9:883-896.
54. Rossel M, et al. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations. Oncogene 1997;14:265-275.
55. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-1331.
56. Mograbi B, Boociardi R, Bourget I, Busca R, Rochet N, Farahi-Far D, Juhel T, Rossi B. Glial cell line-derived neurotrophic factor-stimulated phosphatidylinositol 3-kinase and Akt activities exert opposing effects on the ERK pathway: importance for the rescue of neuroectodermic cells. J Biol Chem 2001;276:45307-45319.
57. Hee Han B, Holtzman DM. BDNF protects the neonatal brain from hypoxyc-ischaemic injury in vivo via the ERK pathway. J Neurosci 2000;20:5775-5781.
58. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Diff 2001;12:397-408.
59. Xue L, Murray JH, Tolkovsky AM. The Ras/phosphatidylinositol 3-kinase and Ras/ERK pathways function as independent survival modules each of which inhibits a distinct apoptotic signaling pathway in sympathetic neurons. J Biol Chem 2000;275:8817-8824.
60. Mazzoni IE, Said FA, Aloyz R, Miller FD, Kaplan D. Ras regulates sympathetic neuron survival by suppressing the p53-mediated cell death pathway. J Neurosci 1999;19:9716-9727.
61. Guyton KZ, Liu Y, Gorospe M, Xu Q, Holbrook NJ. Activation of mitogen-activated protein kinase by H2O2. Role in cell survival following oxidant injury. J Biol Chem 1996;271:4138-4142.
62. Heumann R, et al. Transgenic activation of Ras in neurons promotes hypertrophy and protects from lesion-induced degeneration. J Cell Biol 2000;151:1537-1548.
63. Murray B, Alessandrini A, Cole AJ, Yee AG, Furshpan EJ. Inhibition of the p44/42 MAP kinase pathway protects hippocampal neurons in a cell-culture model of seizure activity. Proc Natl Acad Sci USA 1998;95:11975-11980.
64. Alessandrini A, Namura S, Moskowitz MA, Bonventre JV. MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc Natl Acad Sci USA 1999;96:12866-12869.
65. 2+-induced ERK activation mediated by reactive oxygen species causes cell death in differentiated PC12 cells. J Neurochem 2001;78:600-610.
66. Mori T, Wang X, Jung JC, Sumii T, Singhal AB, Fini ME, Dixon CE, Alessandrini A, Lo EH. Mitogen-activated protein kinase inhibition in traumatic brain injury: in vitro and in vivo effects. J Cereb Blood Flow Metab 2002;22:444-452.
67. Sugino T, Nozaki K, Takagi Y, Hattori I, Hashimoto N, Moriguchi T, Nishida E. Activation of mitogen-activated protein kinases after transient forebrain ischaemia in gerbil hippocampus. J Neurosci 2000;20:4506-4514.
68. Kulich SM, Chu CT. Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J Neurochem 2001;77:1058-1066.
69. Langston JW, Langston EB, Irwin I. MPTP-induced parkinsonism in human and non-human primates-clinical and experimental aspects. Acta Neurol Scand Suppl 1984;100:49-54.
70. Zuddas A, Corsini GU, Schinelli S, Johannessen JN, di Porzio U, Kopin IJ. MPTP treatment combined with ethanol or acetaldehyde selectively destroys dopaminergic neurons in mouse substantia nigra. Brain Res 1989;501:1-10.
71. Bankiewicz KS, Plunkett RJ, Jacobowitz DM, Porrino L, di Porzio U, London WT, Kopin IJ, Oldfield EH, The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism. Histochemical and behavioral studies. J Neurosurg 1990;72:231-244.
72. Zuddas A, Corsini GU, Barker JL, Kopin IJ, Di Porzio U. Specific Reinnervation of Lesioned Mouse Striatum by Grafted Mesencephalic Dopaminergic Neurons. Eur J Neurosci 1991;3:72-85.
73. Perrone-Capano C, Pernas-Alonso R, di Porzio U. Development of midbrain dopaminergic neurons. In: di Porzio U, Perrone-Capano C, Pernas-Alonso R, editors. Dopaminergic neuron development. Austin: Landes Co. 1999. p 37-57.
74. Gomez-Santos C, Ferrer I, Reiriz J, Vinals F, Barrachina M, Ambrosio S. MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res 2002;935:32-39.
75. Zhu JH, Kulich SM, Oury TD, Chu CT. Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. Am J Pathol 2002;161:2087-2098.
76. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 2001;21:4125-4133.
77. Russo C, Dolcini V, Salis S, Venezia V, Zambrano N, Russo T, Schettini G. Signal transduction through tyrosine-phosphorylated C-terminal fragments of amyloid precursor protein via an enhanced interaction with Shc/Grb2 adaptor proteins in reactive astrocytes of Alzheimer's disease brain. J Biol Chem 2002;277:35282-35288.
78. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-6473.
79. Pernas-Alosno R, Perrone-Capano C, Volpicelli F, di Porzio U. Regionalized neurofilament accumulation and motoneuron degeneration are linked phenotypes in wobbler neuromuscular disease. Neurobiol Dis 2001;8:581-589.
80. Zhu X, Lee HG, Raina AK, Perry G, Smith MA. The role of mitogen-activated protein kinase pathways in mer's disease. Neurosignals 2002 Sep-Oct;11:270-281.
81. Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci 2000;23: S117-S126.
82. Calabresi P, Gubellini P, Picconi B, Centonze D, Pisani A, Bonsi P, Greengard P, Hipskind RA, Borrelli E, Bernardi G. Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J Neurosci 2001;21:5110-5120.
83. Brami-Cherrier K, Valjent E, Garcia M, Pages C, Hipskind RA, Caboche J. Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation. J Neurosci 2002;22:8911-8921.
84. Gerfen CR, Miyachi S, Paletzki R, Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 2002;22:5042-5054.
85. Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 1996;36:83-106.
86. Stanciu M, et al. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J Biol Chem 2000;275:12200-12206.
87. Stanciu M, DeFranco DB. Prolonged nuclear retention of activated extracellular signal-regulated protein kinase promotes cell death generated by oxidative toxicity or proteasome inhibition in a neuronal cell line. J Biol Chem 2002;277:4010-4017.
88. Bhalla US, Ram PT, Iyengar R. MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 2000;297:1018-1023.
89. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237:1154-1162.